Revised model factoring in PCM-075 (AML drug) as the key driver of the company going forward - sets $4 target price.

Maxim Group upgrades Trovagene from a "hold" position to a "buy" position based on PCM-075 (AML drug candidate) as the key driver of the company going forward

Announces restructuring program to support its expansion into precision cancer therapeutics

Authors conclude that ctDNA testing demonstrates clinical utility in assessing disease burden and response to therapy

Performance of Trovera™ ctDNA KRAS in blood and urine has similar concordance to standard of care tissue molecular diagnostics

Seven new partners to commercialize Trovera™ liquid biopsy tests in Europe and the Middle East

Companies to develop and commercialize multiplexed urine and blood ctDNA liquid biopsy assay kits for global distribution

Trovera™ liquid biopsy test selected by the Pancreatic Cancer Action Network for its industry-leading sensitivity and ability to rapidly and quantitatively assess response to therapy

BCBS Illinois expands patient access to Trovera™ tests for 8.1 million covered lives

Author concludes that confirmation of EGFR mutational status using urine ctDNA analysis should be considered in treatment decision-making

Data confirms EGFR Activating Mutations and EGFR T790M in metastatic non-small cell lung cancer (NSCLC) diagnosis in urine and blood with high sensitivity and specificity

Trovagene's KRAS ctDNA liquid biopsy test will be at the forefront of research partnership with Dr. Diane Simeone at University of Michigan Health System

Results validate urine ctDNA testing as an alternative to tissue and plasma based on a large prospective study of T790M detection and patient response to an EGFR tyrosine kinase inhibitor

Results from 213 patient study demonstrates use of urinary ctDNA as a stand-alone test for the highly sensitive detection of EGFR T790M mutations for therapy selection

92.9% of metastatic pancreatic cancer patients determined to be KRAS positive using Trovagene's Precision Cancer Monitoring assay

Confirmation of BRAF V600E mutational status and quantitative monitoring of changes in urinary ctDNA used to assess response to novel combination drug therapy for colorectal neuroendocrine tumors

Urinary liquid biopsy shown to monitor early drug response to anti-EGFR therapy

High clinical sensitivity and longitudinal monitoring of KRAS mutations across multiple cancer types demonstrated in urine

Ultra-high sensitivity drives clinical applications and pharmacodynamic monitoring in late-stage cancer patients

Agreement expands in-network health benefit access to Trovagene's Precision Cancer Monitoring platform for an additional 68 million covered lives

FedMed brings in-network health plan access to an additional 40 million covered lives

Agreement provides in-network coverage for 22 million individuals

Stifel 2015 Healthcare Conference and Cannacord Genuity Medical Technologies and Diagnostics Forum

Interim results from a colorectal cancer study adds to the body of clinical evidence supporting Trovagene's urinary ctDNA platform for the detection and monitoring of actionable oncogene mutations using a non-invasive sample

Data for the detection and monitoring of EGFR T790M mutations to be presented at the AACR-NCI-EORTC International Conference

Consistent with prior clinical study results, non-invasive laboratory test is effective in determining mutational status

Quantitative detection and monitoring of circulating tumor DNA (ctDNA) and driver mutations can be used to rapidly detect treatment response

Data presented at the 30th International Papillomavirus Conference; general population screening trial is ongoing

Trovagene Research Institute aims to improve cancer care through advanced genomic solutions with the mission of accelerating adoption of Trovagene's Precision Cancer Monitoring platform in translational research and clinical applications

Clinical Data to be Presented in Oral Session on Liquid Biopsies at the 16th World Conference on Lung Cancer

Clinical data in lung, colorectal, and pancreatic cancer demonstrate the utility of Trovagene's Precision Cancer Monitoring platform as an important disease management tool

Study objective is to deliver a urinary liquid biopsy-based solution to provide faster and more accurate information for measuring response to immunotherapy

Data support the clinical utility of using the Company's Precision Cancer Monitoring technology in the management of non-small cell lung and colorectal cancers

Expanded physician access program, new awareness campaign, and clinical data presentations at ASCO highlight the Company's urine-based liquid biopsy service

Precision Cancer Monitoring technology offers advantages over tissue biopsy and demonstrates ability to monitor tumor dynamics in lung, pancreatic, and colon cancers

Company moves three EGFR mutation assays into its CLIA lab, expands clinical study programs in lung cancer, and prepares to deploy commercial strategy and sales team ahead of ASCO

Analysis concludes that use of Trovagene's urinary liquid biopsy significantly reduces costs when compared to tissue biopsy

Presentation to include results from PREDICTORS 4 study showing high sensitivity and potential for non-invasive test to be made available to millions of women who are unscreened for cervical cancer risk

Company's liquid biopsy technology features single molecule sensitivity and the ability to obtain significantly more circulating tumor DNA (ctDNA) from urine samples vs. plasma

Non-invasive liquid biopsy enables detection of emerging T790M mutations with greater sensitivity than tissue biopsy and months before detection of cancer progression with imaging

Industry leader with strong track record for commercializing disruptive life science and diagnostic technologies, and leveraging innovative applications of next-generation sequencing

Advancing Its Precision Cancer Monitoring Platform Using Liquid Biopsy to Improve the Standard of Cancer Care

Large-scale study shows potential for non-invasive test to be made available to millions of women worldwide who are unscreened for the detection of cervical cancer

Prospective clinical studies to evaluate Trovagene's Precision Cancer Monitoring platform to determine the emergence of resistance mutations using circulating tumor DNA

Trovagene's proprietary KRAS assay enables physicians to determine mutational status, monitor treatment response, and use genomics to aid in predicting patient prognosis

Company expands lung cancer clinical program for its Precision Cancer MonitoringSM solution to up to 700 patients at three leading cancer centers

Company continues to expand its clinical collaborations with National Comprehensive Cancer Network centers across a broad range of clinically actionable mutations in major cancer types